Key result
Home use of warfarin or DOACs was not associated with an increased risk of in-hospital major bleeding compared with no anticoagulant in patients with MI and atrial fibrillation.
Why the study?
To examine patient characteristics, peri-infarction invasive and pharmacologic management, and in-hospital major bleeding in myocardial infarction patients with atrial fibrillation or flutter based on home anticoagulant use.
Does home use of warfarin or DOACs increase in-hospital major bleeding in patients with myocardial infarction and atrial fibrillation compared to no anticoagulant?
Observational (n=26,425)
Yes
Does home use of warfarin or DOACs increase in-hospital major bleeding in patients with myocardial infarction and atrial fibrillation compared to no anticoagulant?
Home use of warfarin or DOACs prior to admission for myocardial infarction is not associated with an increased risk of in-hospital major bleeding compared to no anticoagulant use.
Answers are grounded in this paper and cite their sources.
Reassuring lack of bleeding signal with home anticoagulation in MI with AF; leaves open need for randomized confirmation before practice change.
Background We sought to examine patient characteristics, peri-infarction invasive and pharmacologic management, and in-hospital major bleeding in myocardial infarction patients with atrial fibrillation or flutter, based on home anticoagulant use. Methods and Results We stratified patients by home anticoagulant: (1) no anticoagulant, (2) warfarin, and (3) direct oral anticoagulants ( DOAC s) among ST-segment-elevation myocardial infarction ( STEMI ) and non-STEMI (NSTEMI) patients with atrial fibrillation or flutter treated at 761 US hospitals in the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry from January 2015 to December 2016. The primary outcome of our study was in-hospital major bleeding. Multivariable logistic regression was used to examine the independent association between home anticoagulant and in-hospital major bleeding. Among 6471 STEMI patients with atrial fibrillation or flutter, 15.7% were on warfarin and 13.0% on DOAC s; among 19 954 NSTEMI patients, 22.8% were on warfarin and 15.4% on DOAC s. In STEMI , door-to-balloon times were slightly higher in those on anticoagulant, with similar rates of angiography within 24 hours in the 3 groups. NSTEMI patients on anticoagulant were less likely to undergo angiography (49.3% no anticoagulant, 33.4% on warfarin, 36.4% on DOAC s; P<0.01) or percutaneous coronary intervention within 24 hours (21.1% no anticoagulant, 14.3% on warfarin, 15.9% on DOAC s; P<0.01). After multivariate adjustment, use of home warfarin (odds ratio: 1.00 [95% CI , 0.79-1.27] in STEMI and 1.13 [95% CI , 0.97-1.30] in NSTEMI ) or DOAC (odds ratio: 0.93 [95% CI , 0.73-1.20] in STEMI and 0.97 [95% CI , 0.81-1.16] in NSTEMI ) was not associated with increased in-hospital major bleeding compared with no anticoagulant. Conclusions In routine clinical practice, home warfarin or DOAC therapy is not associated with an increased risk of in-hospital bleeding compared with no anticoagulant.
No takes yet. Share an insight, caveat, or question.
Feldman et al. (2019) conducted an observational in Myocardial infarction with atrial fibrillation or flutter (n=26,425). Home anticoagulant (warfarin or DOAC) vs. No anticoagulant was evaluated on in-hospital major bleeding (OR 0.97, 95% CI 0.81-1.16). Home use of warfarin or DOACs was not associated with an increased risk of in-hospital major bleeding compared with no anticoagulant in patients with MI and atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: